Transforming CLL management with immunotherapy: Investigating the potential of CAR T-cells and bispecific antibodies
{{output}}
Immunotherapies, such as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies or T-cell engagers, have revolutionized the treatment landscape for various B-cell malignancies, including B-acute lymphoblastic leukemia and many non-Hodgkin lym... ...
